American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
By A. Benson, D. Schrag, M. Somerfield, A. Cohen, A. Figueredo, P. Flynn, M. Krzyzanowska, J. Maroun, Pamela K. McAllister, E. Van Cutsem and 3 more. Journal of Clinical Oncology, 2004
1,405 citations recorded by the source corpus.
Subfields: Oncology
View Paper: https://www.semanticscholar.org/paper/65c5064c306c85f12829d166a138c23076e03833
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, background): “• For patients who have stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [19, 20] (CQ-12).”
- Awareness and current knowledge of breast cancer (2017, background): “According to the American cancer society the medicines include in chemotherapy are Docetaxel, Paclitaxel, Platinum agents (cisplatin, carboplatin), Vinorelbine (Navelbine), Capecitabine (Xeloda), Liposomal doxorubicin (Doxil), Cyclophosphamide (Cytoxan), Carboplatin (Paraplatin) etc [204].”
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “Surgery and radiation can be given to patients to supplement a chemotherapeutic plan to curb the disease by destroying shrouded cancer cells that could not be targeted otherwise.(72) Sometimes adjuvant chemotherapy is given to patients after surgery or radiation or both to lessen the chances of recu”
- In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. (2009, methodology): “Patients with high densities of CD45RO and CD8 cells in both tumor regions ([4]-Hi) were at low risk, with 5-year disease-free and overall survival rates of 95.”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, background): “• For patients who have Stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [51, 52] (CQ-14).”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, background): “• For patients who have Stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [51, 52] (CQ-14).”
- Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. (2011, background): “Adjuvant chemotherapy is routinely recommended after curative surgical resectionofstageII-III rectalcancer, stage III (node-positive) colon cancer, and stage II (node-negative) colon cancer in which high-risk features are present.(3,4) However, the optimal time from surgery to the start of chemother”